RecruitingNot applicableNCT05655078
Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University College, London
- Principal Investigator
- Crispin HileyUniversity College, London
- Intervention
- Proton beam therapy(radiation)
- Enrollment
- 148 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2029
Study locations (25)
- East Sussex Healthcare NHS Trust - Eastbourne Hospital, Eastbourne, East Sussex, United Kingdom
- East Sussex Healthcare NHS Trust - Conquest Hospital, Saint Leonards-on-Sea, East Sussex, United Kingdom
- Royal Berkshire Hospital, Reading, England, United Kingdom
- Southend University Hospital, Southend, Essex, United Kingdom
- Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom
- Queen Elizabeth Hospital, King's Lynn, Kings Lynn, Norfolk, United Kingdom
- Furness General Hospital, Barrow in Furness, United Kingdom
- Betsi Cadwaladr University Health Board -Glan Clwyd Hospital, Bodelwyddan, United Kingdom
- Southmead Hospital, Bristol, United Kingdom
- Addenbrooke's Hospital, Cambridge, United Kingdom
- Velindre Cancer Centre, Cardiff, United Kingdom
- Broomfield Hospital, Chelmsford, United Kingdom
- Queens Centre, Castle Hill Hospital, Hull, United Kingdom
- Royal Lancaster Hospital, Lancaster, United Kingdom
- St James University Hospital, Leeds, United Kingdom
- +10 more locations on ClinicalTrials.gov
Collaborators
Asthma + Lung UK · Mesothelioma UK · University of Sheffield
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05655078 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06790082The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural MesotheliomaAalborg University Hospital
- RECRUITINGPHASE1NCT06566079Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid TumorsInSilico Medicine Hong Kong Limited